Immunotoxins targeting B cell malignancy-progress and problems with immunogenicity

Daniel A. Vallera, Robert J. Kreitman

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.

Original languageEnglish (US)
Article number1
Issue number1
StatePublished - Mar 1 2019

Bibliographical note

Funding Information:
This work was supported in part by the U.S. Public Health Service Grant R01-CA36725 awarded by the NCI and the NIAID, DHHS, the Lion Fund, the Randy Shaver Foundation, and a CETI translational award from the University of Minnesota Masonic Cancer Center

Publisher Copyright:
© 2019 by the authors.


  • B-cell malignancies
  • CD19
  • CD22
  • Chemo-immunosuppression
  • Deimmunized
  • Diphtheria toxin
  • Immunogenicity
  • Immunotoxin
  • Pseudomonas exotoxin


Dive into the research topics of 'Immunotoxins targeting B cell malignancy-progress and problems with immunogenicity'. Together they form a unique fingerprint.

Cite this